bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel ...

Retrieved on: 2021-12-18 14:01:42

Tags for this article:

Branches of biology

Health

Rare diseases

Breakthrough therapy

Leukodystrophies

Elivaldogene autotemcel

u.s. food and drug administration

Click the tags to see associated articles and topics

bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel .... View article details on HISWAI: https://pipelinereview.com/index.php/2021121879982/DNA-RNA-and-Cells/bluebird-bio-Announces-FDA-Priority-Review-of-Biologics-License-Application-for-eli-cel-Gene-Therapy-for-Cerebral-Adrenoleukodystrophy-CALD-in-Patients-Without-a-Matche.html

Excerpt

... autotemcel (eli-cel, Lenti-D®), the company's gene therapy for cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age.

Article found on: pipelinereview.com

View Original Article